Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8740641 | Journal of Infection and Chemotherapy | 2018 | 4 Pages |
Abstract
In summary, this study showed that fidaxomicin was active against a number of Clostridium spp., including C. difficile. Fidaxomicin was generally more effective than its major metabolite OP-1118, but both showed a similar spectrum of activity, suggesting that OP-1118 contributes to the antimicrobial activity of fidaxomicin. These findings were broadly in accordance with those of similar studies conducted in other settings.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Katsunori Yanagihara, Norihiko Akamatsu, Junichi Matsuda, Norihito Kaku, Kiyomitsu Katsumata, Kosuke Kosai,